<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors describe the development of bladder <z:hpo ids='HP_0003470'>paralysis</z:hpo> in a child with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> undergoing maintenance chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Immediately before the adverse clinical event, the child had received <z:chebi fb="0" ids="28445">vincristine</z:chebi> intravenously and triple therapy with <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi>, <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> intrathecally and had begun a 5-day pulse of <z:chebi fb="2" ids="8378">prednisolone</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The authors conclude that the ensuing reversible bladder <z:hpo ids='HP_0003470'>paralysis</z:hpo> was related to the <z:chebi fb="0" ids="28445">vincristine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The clinical event resolved, and <z:chebi fb="0" ids="28445">vincristine</z:chebi> was deleted from the child's subsequent therapy until full recovery was achieved </plain></SENT>
<SENT sid="4" pm="."><plain>The authors advise recognition of this problem and discontinuation of the <z:chebi fb="0" ids="28445">vincristine</z:chebi> if transient bladder <z:hpo ids='HP_0003470'>paralysis</z:hpo> develops until symptoms completely disappear </plain></SENT>
</text></document>